CoLucid Pharmaceuticals Inc. (CLCD) Shares Down 1.6%
CoLucid Pharmaceuticals Inc. (NASDAQ:CLCD) dropped 1.6% during mid-day trading on Thursday . The stock traded as low as $8.39 and last traded at $8.55, with a volume of 77,758 shares changing hands. The stock had previously closed at $8.69.
Separately, Zacks Investment Research raised shares of CoLucid Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, June 17th.
The company’s market cap is $130.95 million. The stock’s 50 day moving average is $8.87 and its 200 day moving average is $7.03.
CoLucid Pharmaceuticals (NASDAQ:CLCD) last issued its quarterly earnings results on Wednesday, August 10th. The biopharmaceutical company reported ($1.06) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.84) by $0.22. On average, equities research analysts anticipate that CoLucid Pharmaceuticals Inc. will post ($4.01) earnings per share for the current fiscal year.
In other CoLucid Pharmaceuticals news, major shareholder Domain Partners Vi, L.P. sold 153,028 shares of the company’s stock in a transaction dated Wednesday, August 3rd. The shares were sold at an average price of $8.45, for a total transaction of $1,293,086.60. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.
CoLucid Pharmaceuticals, Inc is a Phase III clinical-stage biopharmaceutical company. The Company is engaged in developing a small molecule for the acute treatment of migraine headaches. Its product candidates address the needs of migraine patients, including those with cardiovascular risk factors or stable cardiovascular disease and those dissatisfied with existing therapies.